One such inhibitor, the first 3rd generation ALK (and ROS1) inhibitor PF-06463922 (lorlatinib), exhibits increased potency against F1174L, 1151Tins, I1171T and G1269A in preclinical EML4-ALK models [67, 68], with impressive anti-tumour activity observed in xenograft neuroblastoma models harboring F1174L [53]. Here, EML4 is linked to neuroblastoma.